- Could you give us a brief overview of the disease burden of advanced systemic mastocytosis and the unmet needs in its treatment? (0:26)
- What was the rationale for investigating avapritinib in the treatment of patients with advanced systemic mastocytosis? (1:04)
- Could you tell us a little about the PATHFINDER study and its findings? (1:39)
- How clinically meaningful are these benefits? (2:35)
Link to the video: Marcus Maurer, EAACI 2021: Avapritinib for Advanced Systemic Mastocytosis - The PATHFINDER Study - touchIMMUNOLOGY
Filmed in coverage of the 2021 EAACI Annual Meeting.